Each gram of cream/ointment/gel contains: Clobetasol propionate 0.5 mg.
As other corticosteroids, Clobetasol propionate has topical anti inflammatory characteristics. Corticosteroids act through the induction of phospholipase A2 inhibitor proteins, collectively known as lipocortine. It is postulated that these proteins modulate the biosynthesis of inflammatory mediators, e.g. prostaglandins and leucotrienes, by inhibiting their precursor (i.e Arachidonic acid) release. Arachidonic acid is released from phospholipids membrane by phospholipase A2.
Short-term treatment of resistant dermatoses, e.g. psoriasis (not including widespread psoriasis), recalcitrant dermatitis, lichen planus, discoid lupus erythematosus, and other dermatoses which do not respond satisfactorily to less potent corticosteroid preparations.
Apply sparingly to the affected area once or twice daily until improvement occurs and discontinue when control is achieved. In the more responsive conditions, this may be within a few days. Treatment should not exceed two consecutive weeks and the total dose should not exceed 50 g per week as there is a Hypothalamic-Pituitary-Adrenal (HPA) axis suppressing potential. Reconsider the diagnosis if there is no improvement after two weeks treatment. If long-term corticosteroid treatment is needed, a low potency preparation should be used.
Elopro cream 10 g: The product can be used within 35 days after opened.
Elopro ointment 10 g: The product can be used within 35 days after opened.
Elopro gel 10 g: The product can be used within 35 days after opened.
Patients with hypersensitivity to Clobetasol propionate, other corticosteroids, or any other component of Elopro.
Rosaceae, acne vulgaris, and perioral dermatitis, skin lesions caused by viruses infection (e.g. Herpes simplex and chicken pox).
Treatment of skin lesions caused by fungal or bacterial infection, genital, and perianal pruritus.
Dermatoses in children less than one year old including dermatitis and diaper rash.
Long-term continuous therapy should be avoided, particularly in children, in whom adrenal suppression may occur readily. If Elopro is required for use in children, courses should be limited to 5 days, and weekly evaluation should be done.
The face, more than other areas of the body, may exhibit atrophic changes after prolonged treatment with potent topical corticosteroids.
If applied to the eyelids, care is needed to ensure that Elopro does not enter the eye, as glaucoma might result. Topical antibiotics should be given whenever treating inflammatory lesions which are prone to infection.
Caution should be exercised when given to pregnant and nursing women.
Clobetasol propionate is usually well-tolerated in 2 weeks treatment. Frequently reported adverse effects are burning and stinging sensation.
Prolonged, excessive use over large surface area may augment systemic absorption which may result in symptoms and sign of corticosteroid excess (Adrenal suppression, Cushing's syndrome, hyperglycemia, and hypertension).
Long-term and intensive treatment with high potency corticosteroid preparations may cause local atrophic changes, e.g. thinning of the skin, striae, and dilatation of superficial blood vessels particularly when occlusive dressings are used or when skin folds are involved.
D07AD01 - clobetasol ; Belongs to the class of very potent (group IV) corticosteroids. Used in the treatment of dermatological diseases.
Elopro cream 0.05 %
10 g x 1's
Elopro oint 0.05 %
10 g x 1's
Elopro topical gel 0.05 %
10 g x 1's
Sign Out
